For life sciences companies that have moved from development into commercial production, inventory quickly becomes one of the largest and most judgment-heavy balances on the balance sheet. The guidance in ASC 330, Inventory, is not new, but contract manufacturing arrangements, batch release requirements, and the line between research and commercial activity make the cost of a finished vial or bottle harder to pin down in this industry than in most others, and that cost is the starting point for every net realizable value analysis that follows.
Building the Cost of Inventory
ASC 330 defines the cost of inventory as the sum of the expenditures and charges incurred, directly or indirectly, in bringing a product to its existing condition and location. In practice, that calculation has three layers. The first is materials: active pharmaceutical ingredient (API), excipients, vials, stoppers, labels, and cartons, along with inbound freight, duties, and other costs to get those materials to the manufacturing site, net of any purchase discounts. The second is direct labor for the people who compound, fill, package, and inspect the product. The third is production overhead, which covers both variable costs, such as utilities and supplies consumed on the line, and fixed costs, such as depreciation of the facility and equipment, maintenance, production supervision, and quality-control testing required before a batch can be released for sale.
Companies that outsource production to a contract development and manufacturing organization (CDMO) follow the same logic, even though the invoice replaces much of the in-house labor and overhead. The CDMO’s manufacturing and fill-finish fees, the API the company purchases and ships to the CDMO, and batch release testing performed before product is available for sale are generally capitalized, along with inbound shipping and import costs, including customs duties and tariffs. Internal costs can also qualify when they relate directly to production, such as supply chain or quality personnel whose time is spent overseeing batches, provided the allocation method is reasonable and applied consistently.
Costs That Stay Out
Just as important is what the calculation excludes. Selling, general, and administrative costs are period expenses, as are outbound freight to customers and, in most cases, storage of finished goods once they are ready for sale. In practice, storage costs are generally includable only when the storage is a necessary part of the production process itself, such as holding a batch in quarantine pending quality release, or when it represents raw material or work-in-process storage during the normal manufacturing cycle. Research and development costs are expensed under ASC 730, which captures clinical trial material and, commonly, product manufactured before regulatory approval. Some companies capitalize pre-launch inventory once approval is judged probable, and whichever policy a company chooses needs to be documented and disclosed. Technology transfer fees paid to bring a process into a new CDMO are another frequent question, and they are generally not part of the cost of any particular batch.
Abnormal costs are also excluded. Fixed overhead is allocated based on the normal capacity of the facility, so amounts resulting from abnormally low production, idle facility expense, and wasted materials from a failed batch outside normal yield expectations are charged to expense as incurred. This tends to matter most in the first year after a launch, when output often runs well below what a plant was built to handle.
A Worked Example
Assume a generic injectable company has a CDMO produce a batch of 50,000 vials. The company incurs $100,000 for API, $25,000 for excipients and packaging components, $75,000 in CDMO fill-finish fees, $10,000 for batch release testing, $5,000 of inbound freight, and allocates $15,000 of internal quality and supply chain costs directly tied to the batch. The capitalized cost is $230,000, or $4.60 per vial. Assume the company also paid $20,000 in technology transfer fees and expects to spend $8,000 to ship finished vials to wholesalers. Neither amount belongs in inventory, and including them would overstate the cost per vial by $0.56 ($28,000 divided by 50,000).
Where Net Realizable Value Comes In
Typically, life sciences companies report inventory using FIFO or average cost, and they are required to measure inventory at the lower of cost and net realizable value (NRV), which is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. That second half of the definition is where the selling costs excluded from inventory come back into the picture: outbound freight, third-party logistics fees paid to service providers, sales commissions, and other costs required to sell the product are never capitalized, but they are subtracted from the expected selling price when measuring NRV. In the generic and specialty space, the selling price itself is the net price after chargebacks, rebates, and wholesaler and group purchasing organization fees, not wholesale acquisition cost. Our article on gross-to-net discusses how far those two figures can drift apart.
Returning to the example, assume a new competitor pushes the expected net price to $5.10 per vial. Assume the company expects to incur $0.16 per vial in outbound freight (the $8,000 shipping cost divided by 50,000 vials), $0.30 per vial in third-party logistics fees, and $0.14 per vial in sales commissions, for total costs to sell of $0.60. NRV is $4.50 ($5.10 less $0.60), and the company records a $5,000 write-down ($0.10 on each of 50,000 vials). Had the costs to sell been left out, NRV would have appeared to be $5.10, comfortably above cost, and the write-down would have been missed entirely. Once inventory is written down, the lower amount becomes its new cost basis.
Takeaway
Getting inventory right starts long before year-end. Companies moving into commercial production should document which costs they capitalize and why, revisit normal capacity assumptions as output ramps up after launch, and update NRV analyses as pricing, competition, or distribution costs change, not just at year-end. A clear, consistently applied policy also makes it easier to support accounting decisions during an audit, rather than reconstructing them after a write-down.
For more information on inventory accounting considerations specific to the life sciences industry, visit our Life Sciences practice page.

